bs-1557G-Cy3 [Conjugated Primary Antibody]
HBsAg Polyclonal Antibody, Cy3 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Goat

Target Protein: HBsAg

Clonality: Polyclonal

Isotype: IgG

Swiss Prot: Q67926

Source: Human Hepatitis B Surface Antigen

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Hepatitis B Virus (HBV) infection induces a disease state characterised by liver damage, inflammation and viral persistence. Infection also increases the risk of hepatocellular carcinoma. HBV belongs to the Hepadnaviridae family of viruses. Its genome consists of partially double stranded circular DNA. The DNA is enclosed in a nucleocapsid, or core antigen (HBcAg), which is surrounded by a spherical envelope (surface antigen or HBsAg). The core antigen shares its sequences with the e antigen (HBeAg) but no cross reactivity between the two proteins has been observed. The HBV genome also encodes a DNA polymerase that also acts as a reverse transcriptase. Hepatitis B infection is normally diagnosed from serological tests that detect HBsAg but as the disease progresses this antigen may no longer be present in the blood and tests for HBcAg are used. If HBsAg can be detected in the blood for longer than six months, chronic hepatitis B is diagnosed. The antigenic determinant of the protein moiety of the HBsAg determines specific characteristics of different serotypes and provides the basis of immunodetection. HBsAg has antigenic heterogeneity, specifically, two pairs of sub specific determinants, d/y and w/r allow the following combinations: adw, ayw, adr, ayr.

Conjugation: Cy3

Excitation/ Emission: 512,550nm/570,615nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 44


Cross Reactive Species: Human
Mouse
Virus

Predicted Cross Reactive Species: Bee

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Ma, Yan-Xiu, et al. "Successful establishment and evaluation of a new animal model for studying the hepatitis B virus YVDD mutant." Archives of virology (2012): 1-7.Read more>>
  • Watanabe, Tsunamasa, et al. "Post-Exposure Prophylactic Effect of HBV-active Antiretroviral Therapy Against Hepatitis B Virus Infection." Antimicrobial Agents and Chemotherapy (2014): AAC-04459.Read more>>
  • Okumura, Nobuaki, et al. "Negative regulation of hepatitis B virus replication by forkhead box protein A in human hepatoma cells." FEBS Letters (2015).Read more>>
  • Nakabori, T., et al. "Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver."Scientific reports 6 (2015): 27782-27782.Read more>>
  • Xiang, A., et al. "A simple and rapid capillary chemiluminescence immunoassay for quantitatively detecting human serum HBsAg." European journal of clinical microbiology & infectious diseases 32.12 (2013): 1557-1564.Read more>>
  • Ito, H., et al. "Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin‐1 ligand." Journal of Viral Hepatitis (2016).Read more>>
  • Yu, Hao-Tong, et al. "Comparison of the patterns of antibody recall responses to HIV-1 gp120 and hepatitis B surface antigen in immunized mice." Vaccine (2016).Read more>>
  • Lai, M. W., et al. "Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation." Oncogenesis 5.12 (2016): e273.Read more>>
  • Sakurai, Fuminori, et al. "Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection." Scientific Reports 7 (2017): 45698.Read more>>
  • Gong et al. Construction and expression of a recombinant eukaryotic expression plasmid containing the preS1-preS2-S genes of hepatitis B virus and the granulocyte-macrophage colony stimulating factor gene: A study of its immunomodulatory effects. (2013) Biomed.Re. 1:251-256Read more>>
  • Kong et al. The enhanced expression of death receptor 5 (DR5) mediated by HBV X protein through NF-kappaB pathway is associated with cell apoptosis induced by (TNF-α related apoptosis inducing ligand) TRAIL in hepatoma cells. (2015) Virol.J. 12:192Read more>>
  • Okumura et al. Negative regulation of hepatitis B virus replication by forkhead box protein A in human hepatoma cells. (2015) FEBS.Lett. 589:1112-8Read more>>
  • Yuki Takamatsu. et al. A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes. VIRUS RES. 2023 May;329:199094Read more>>
  • Ito Daisuke. et al. Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice. Hepatology Communications. 2023 Mar;7(4):e0104Read more>>
  • Ouchida Tsunenori. et al. The specific core fucose-binding lectin Pholiota squarrosa lectin (PhoSL) inhibits hepatitis B virus infection in vitro. SCI REP-UK. 2023 Apr;13(1):1-12Read more>>
  • Kong Huimin. et al. An antifouling membrane-fusogenic liposome for effective intracellular delivery in vivo. NAT COMMUN. 2024 May;15(1):1-15Read more>>
VALIDATION IMAGES